Percheron Therapeutics Limited is an Australia-based biotechnology company. The Company is focused on the development and commercialization of novel therapies for oncology and rare diseases. The Company’s lead program is HMBD-002, a monoclonal antibody targeting the immune checkpoint regulator, VISTA. HMBD-002 has completed a phase I clinical trial in patients with advanced cancer. HMBD-002 is a recombinant humanized monoclonal IgG4 antibody to human v-domain immunoglobulin suppressor of T-cell activation (VISTA). VISTA is one of a number of novel immuno-oncology targets under investigation by pharmaceutical companies, with potential applications to a range of solid tumors and hematological malignancies.

• Revenue in AUD (TTM)371.10k
• Net income in AUD-14.92m
• Incorporated2000
• Employees8.00

• Location
  Percheron Therapeutics LtdL30, Collins Place, 35 Collins StreetMELBOURNE 3000AustraliaAUS
• Phone+61 39827-8999
• Fax+61 39859-7701
• Websitehttps://percherontx.com/